Video

Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin Lymphoma

Author(s):

Ayad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine (A + AVD) versus AVD plus bleomycin (ABVD) in patients with Hodgkin lymphoma.

In the United States, ABVD is commonly used in this patient population, says Hamdan; this regimen has been used for decades. Although treatment with regimen leads to favorable results, it is associated with many toxicities are involved. A+AVD, an alternative regimen, is also available and it has shown to have similar, if not better, benefit to that of ABVD.

Hamdan says that he tends to use A+AVD in patients who have stage IV disease or an elevated International Prognostic Score (IPS), as long as they don’t have any concerning comorbidities that would put them at increased risk for neuropathy or neutropenia.

It is unknown how the National Comprehensive Cancer Network guidelines will incorporate brentuximab vedotin, says Hamdan. To date, ABVD is still considered to be the preferred regimen in this space per the guidelines; however, A+AVD is another option available in the frontline setting, concludes Hamdan.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.